Jefferies analyst Matthew Taylor lowered the price target on Boston Scientific (NYSE: BSX) to $100.00 (from $110.00) while maintaining a Buy rating.

The analyst commented, "BSX reported 1Q25 sales of $5.20B +9.4% org, above cons $5.17B and EPS of $0.80 +6%, above cons $0.79. While 1Q was better than expected, new issues arose in urology and CRM, WM slowed, and BSX lowered its '26 org growth guidance to +6.5-8% from +10-11% and EPS to $3.34-3.41 from $3.43-$3.49. We continue to view BSX as undervalued and reit. our Buy rating, but we are lowering our numbers and PT, with BSX now calling 10%+ growth in the LRP an upside scenario."